

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 December 2022 (29.12.2022)



(10) International Publication Number
WO 2022/271724 A1

(51) International Patent Classification:

C12Q 1/6883 (2018.01) G16H 50/20 (2018.01)
G16H 20/10 (2018.01) G16H 10/60 (2018.01)

Waltham, Massachusetts 02453 (US). **VOITALOV, Ivan**;
221 Crescent Street, Suite 103A, Waltham, Massachusetts
02453 (US).

(21) International Application Number:

PCT/US2022/034375

(74) Agent: **CRIPPEN, Shane M.**; Wilson Sonsini, 650 Page
Mill Road, Palo Alto, California 94304 (US).

(22) International Filing Date:

21 June 2022 (21.06.2022)

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/213,431 22 June 2021 (22.06.2021) US
63/329,008 08 April 2022 (08.04.2022) US

(71) Applicant: **SCIPHER MEDICINE CORPORATION**
[US/US]; 221 Crescent Street, Suite 103A, Waltham, Mass-
achusetts 02453 (US).

(72) Inventors: **GHIASSIAN, Susan**; 221 Crescent Street,
Suite 103A, Waltham, Massachusetts 02453 (US). **AK-
MAEV, Viatcheslav R.**; 221 Crescent Street, Suite 103A,

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: METHODS AND SYSTEMS FOR THERAPY MONITORING AND TRIAL DESIGN




FIG. 1

(57) Abstract: Described are methods and systems for identifying a disease gene expression signature determined to revert a disease gene expression signature in a subject suffering from a disease to a non-diseased expression signature (e.g., gene expression of a non-diseased subject). Also provided herein are methods of designing a study (e.g., a clinical trial) comprising identifying diseased subjects who exhibit a quantifiable change in the disease gene expression signature towards gene expression of a non-diseased subject.

[Continued on next page]

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*